BAYER AKTIENGESELLSCHAFT 4
4 · Senti Biosciences, Inc. · Filed Mar 12, 2025
Insider Transaction Report
Form 4
BAYER HEALTHCARE LLC
10% Owner
Transactions
- Conversion
Series A Convertible Preferred Stock
2025-03-10−2,222→ 0 totalFrom: 2025-03-10→ Common Stock (2,222,000 underlying) - Conversion
Common Stock
2025-03-10+2,222,000→ 2,809,848 total
Holdings
- 3,330,000
Warrant
Exercise: $2.30From: 2025-03-10Exp: 2029-12-09→ Common Stock (3,333,000 underlying)
Footnotes (3)
- [F1]Each share of Series A Convertible Preferred Stock ("Series A") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025.
- [F2]The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.
- [F3]The reported securities include shares of Series A and warrants purchased by the reporting person for $2,250 per unit. Each unit consists of one share of Series A, convertible into 1,000 shares of the Issuer's common stock, and accompanying warrant coverage to purchase 1,500 shares of the Issuer's common stock for each share of Series A purchased.